Treatment with lenalidomide modulates T-cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemia

Cancer

Volumn 117, Issue 17, 2011, Pages 3999-4008

  Lee, Bang Ning ^a,c   Gao, Hui ^a   Cohen, Evan N ^a,c   Badoux, Xavier ^b   Wierda, William G ^b   Estrov, Zeev ^b,c   Faderl, Stefan H ^b   Keating, Michael J ^b   Ferrajoli, Alessandra ^b   Reuben, James M ^a,c  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

chronic lymphocytic leukemia; cytokines; immunomodulatory agents; T cells

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; LENALIDOMIDE; T LYMPHOCYTE RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

AGED; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CYTOKINE PRODUCTION; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; FEMALE; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOPHENOTYPING; LYMPHOCYTE COUNT; MALE; MULTIPLE CYCLE TREATMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; CYTOKINES; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOPHENOTYPING; INTERLEUKIN-2; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; T-LYMPHOCYTE SUBSETS; THALIDOMIDE;

EID: 80051928145     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25983     Document Type: Article

References (33)

1. List A, Kurtin S, Roe DJ, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005; 352: 549-557. (Pubitemid 40204668)
2. Richardson PG, Blood E, Mitsiades CS, et al. A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma. Blood 2006; 108: 3458-3464.
3. Hideshima T, Mitsiades C, Tonon G, Richardson PG, Anderson KC,. Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets. Nat Rev Cancer. 2007; 7: 585-598. (Pubitemid 47106630)
4. Pellagatti A, Jadersten M, Forsblom AM, et al. Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q- syndrome patients. Proc Natl Acad Sci U S A. 2007; 104: 11406-11411. (Pubitemid 47175153)
5. Kotla V, Goel S, Nischal S, et al. Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol. 2009; 12: 36-46.
6. Hallek M, Pflug N,. Chronic lymphocytic leukemia. Ann Oncol. 2010; 21 (suppl 7): vii154-vii164.
7. Brown JR,. Immunomodulators in chronic lymphocytic leukemia: where does lenalidomide belong? Leuk Lymphoma. 2010; 51: 1382-1385.
8. Saloura V, Grivas PD,. Lenalidomide: a synthetic compound with an evolving role in cancer management. Hematology. 2010; 15: 318-331.
9. Ferrajoli A, Badoux XC, O'Brien S, et al. Combination therapy with lenalidomide and rituximab in patients with relapsed chronic lymphocytic leukemia(CLL) [abstract]. Blood. 2009; 114 (suppl 1): 89. Abstract 206.
10. Brown JR, Abramson J, Hochberg E, et al. A phase I study of lenalidomide in combination with fludarabine and rituximab in previously untreated CLL/SLL. Leukemia. 2010; 24: 1972-1975.
11. Lapalombella R, Andritsos L, Liu Q, et al. Lenalidomide treatment promotes CD154 expression on CLL cells and enhances production of antibodies by normal B cells through a PI3-kinase-dependent pathway. Blood. 2010; 115: 2619-2629.
12. Gorgun G, Ramsay AG, Holderried TA, et al. E(mu)-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction. Proc Natl Acad Sci U S A. 2009; 106: 6250-6255.
13. Zhang L, Qian Z, Cai Z, et al. Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo. Am J Hematol. 2009; 84: 553-559.
14. Binet JL, Caligaris-Cappio F, Catovsky D, et al. Perspectives on the use of new diagnostic tools in the treatment of chronic lymphocytic leukemia. Blood. 2006; 107: 859-861. (Pubitemid 43156279)
15. Cheson BD, Bennett JM, Grever M, et al. National Cancer Institute-Sponsored Work Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood. 1996; 87: 4990-4997. (Pubitemid 26189840)
16. Reuben JM, Lee BN, Johnson H, Fritsche H, Kantarjian HM, Talpaz M,. Restoration of Th1 cytokine synthesis by T cells of patients with chronic myelogenous leukemia in cytogenetic and hematologic remission with interferon-alpha. Clin Cancer Res. 2000; 6: 1671-1677. (Pubitemid 30305059)
17. Marson A, Kretschmer K, Frampton GM, et al. Foxp3 occupancy and regulation of key target genes during T-cell stimulation. Nature. 2007; 445: 931-935.
18. Lee BN, Duvic M, Tang CK, Bueso-Ramos C, Estrov Z, Reuben JM,. Dysregulated synthesis of intracellular type 1 and type 2 cytokines by T cells of patients with cutaneous T-cell lymphoma. Clin Diagn Lab Immunol. 1999; 6: 79-84. (Pubitemid 29035644)
19. Scrivener S, Goddard RV, Kaminski ER, Prentice AG,. Abnormal T-cell function in B-cell chronic lymphocytic leukaemia. Leuk Lymphoma. 2003; 44: 383-389. (Pubitemid 36118829)
20. Jak M, Mous R, Remmerswaal EB, et al. Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in chronic lymphocytic leukemia. Leuk Lymphoma. 2009; 50: 788-801.
21. Kiaii S, Choudhury A, Mozaffari F, Kimby E, Osterborg A, Mellstedt H,. Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia (B-CLL): comparison of indolent and progressive disease. Med Oncol. 2005; 22: 291-302. (Pubitemid 41176325)
22. Gorgun G, Holderried TA, Zahrieh D, Neuberg D, Gribben JG,. Chronic lymphocytic leukemia cells induce changes in gene expression of CD4 and CD8 T cells. J Clin Invest. 2005; 115: 1797-1805. (Pubitemid 40979718)
23. Fayad L, Keating MJ, Reuben JM, et al. Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome. Blood. 2001; 97: 256-263. (Pubitemid 32061268)
24. Yen Chong S, Lin YC, Czarneski J, et al. Cell cycle effects of IL-10 on malignant B-1 cells. Genes Immun. 2001; 2: 239-247. (Pubitemid 33681705)
25. Djurdjevic P, Zelen I, Ristic P, Baskic D, Popovic S, Arsenijevic N,. Role of decreased production of interleukin-10 and interferon-gamma in spontaneous apoptosis of B-chronic lymphocytic leukemia lymphocytes in vitro. Arch Med Res. 2009; 40: 357-363.
26. Itoh M, Takahashi T, Sakaguchi N, et al. Thymus and autoimmunity: production of CD25+CD4+ naturally anergic and suppressive T cells as a key function of the thymus in maintaining immunologic self-tolerance. J Immunol. 1999; 162: 5317-5326. (Pubitemid 29307138)
27. Vukmanovic-Stejic M, Zhang Y, Cook JE, et al. Human CD4+ CD25hi Foxp3+ regulatory T cells are derived by rapid turnover of memory populations in vivo. J Clin Invest. 2006; 116: 2423-2433. (Pubitemid 44330141)
28. Baecher-Allan C, Brown JA, Freeman GJ, Hafler DA,. CD4+CD25high regulatory cells in human peripheral blood. J Immunol. 2001; 167: 1245-1253. (Pubitemid 32703119)
29. Giannopoulos K, Schmitt M, WÅasiuk P, et al. The high frequency of T regulatory cells in patients with B-cell chronic lymphocytic leukemia is diminished through treatment with thalidomide. Leukemia. 2008; 22: 222-224.
30. Quesada JR, Reuben JM, Scouros MA, Murphy SG,. Autologous mixed lymphocyte reaction in lymphoid malignancies. Lack of correlation with disease activity or clinical remission. Cancer Immunol Immunother. 1982; 12: 231-239. (Pubitemid 12105227)
31. Ferrajoli A, Lee BN, Schlette EJ, et al. Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia. Blood 2008; 111: 5291-5297.
32. Galustian C, Meyer B, Labarthe MC, et al. The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells. Cancer Immunol Immunother. 2009; 58: 1033-1045.
33. Sher T, Miller KC, Lawrence D, et al. Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma. 2010; 51: 85-88.